FDA's "Complete Response" On GTx's Toremifene Moves The Goal Posts, CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Having gone through the special protocol assessment process, the sponsor was surprised by the request for a second pivotal trial and another clinical trial on effects on cancer.